US Market News
1月前
GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes PatientsMay 1, 2026 8:10 AM
Business Wire
Eligible self-pay patients can access the oral diabetes treatment for as low as $149 per month
Brief Summary:
GoodRx expands access to Ozempic® pill (oral semaglutide) for as low as $149 per month
Available at GoodRx’s nationwide pharmacy network
Adds an oral option to the Ozempic treatment portfolio
GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisk’s Ozempic® pill (oral semaglutide), helping eligible patients with type 2 diabetes obtain the medication for as low as $149 per month at pharmacies nationwide.
“As Novo Nordisk brings the Ozempic pill to market, we’re focused on helping patients access it with clear, transparent pricing,” said Wendy Barnes, President & CEO of GoodRx. “The availability of an oral formulation under the Ozempic brand marks an important step forward, offering a convenient alternative to the established injectable. It also reflects GoodRx’s expanding work with Novo Nordisk across the entire semaglutide portfolio and its role in supporting patient access.”
“We’re excited to bring the Ozempic pill to the GoodRx platform – adding a newly approved oral option under a brand people know and trust, and giving healthcare professionals more flexibility to tailor treatment for each patient,” said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. “Working with GoodRx helps expand access to our medicines, now including the Ozempic pill, with a clear self-pay pricing model.”
More broadly, this announcement demonstrates how GoodRx is evolving beyond a pricing solution into a broader consumer access platform for pharmaceutical manufacturers, helping them reach patients directly, convert clinically appropriate demand, and deliver transparent pricing seamlessly at the pharmacy counter.
*The Ozempic pill is now available to eligible self-pay patients at a cash price of $149 per month for the 1.5mg dose, $199 per month for the 4mg dose, and $299 per month for the 9mg dose.
About GoodRx
GoodRx is the leading platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.
?GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
GoodRx Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of our offerings to consumers, GoodRx, Novo Nordisk, and other pharmaceutical manufacturers; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260501334152/en/
Media Contact
press@goodrx.com
Original: GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients
US Market News
2月前
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference CallApril 17, 2026 4:05 PM
Business Wire
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S. markets close on Wednesday, May 6, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 7, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook.
To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company’s investor relations website at https://investors.goodrx.com, where accompanying materials will be posted prior to the conference call.
Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.goodrx.com for at least 30 days.
About GoodRx
GoodRx is the leading platform for prescription savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.
GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260417152984/en/
Investor Contact
GoodRx
ir@goodrx.com
Media Contact
GoodRx
press@goodrx.com
Original: GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call
US Market News
2月前
GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies NationwideApril 9, 2026 7:30 AM
Business Wire
Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx
Brief Summary:
GoodRx is expanding access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron)
Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx
GoodRx is also offering self-pay pricing for Zepbound® (tirzepatide) KwikPen® starting at $299 per month
Foundayo and Zepbound KwikPen are available through GoodRx’s nationwide pharmacy network
GoodRx is helping pharmaceutical manufacturers deliver consumer-direct pricing at scale from day one
GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron). Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available discounted cash price at launch. The offering provides transparent pricing and nationwide pharmacy access for the highly anticipated weight management treatment.
GoodRx is also expanding access to Zepbound® (tirzepatide) KwikPen®, available to eligible self-pay patients starting at $299 per month at more than 70,000 pharmacies nationwide. Together with the launch of Foundayo, these offerings expand access to both oral and injectable GLP-1 treatments for adults seeking prescribed obesity care outside traditional insurance pathways.
“We’re excited to work with Lilly to help bring one of the most anticipated innovations in weight management to patients,” said Wendy Barnes, President and CEO of GoodRx. “As new GLP-1 therapies continue to expand, including oral options like Foundayo, it is critical that access evolves alongside innovation. By pairing transparent cash pricing with nationwide pharmacy access and integrated care, we are helping ensure more people understand their options and more easily start treatment.”
“The launch of Foundayo reflects Lilly’s continued commitment to expanding treatment options for people living with obesity and advancing meaningful innovation in this category,” said Laura Steele, Group Vice President of U.S. Cardiometabolic Health at Eli Lilly and Company. “We're committed to expanding access to treatment options through channels that meet patients where they are in their journey.”
Supporting New Access Models for Drug Launches
GoodRx’s role in expanding access to Foundayo reflects a broader shift in how innovative therapies reach patients. For many medications, particularly GLP-1 treatments prescribed for weight loss, insurance coverage remains inconsistent or unavailable, prompting manufacturers to explore new direct-to-consumer access models. GoodRx supports this shift by combining transparent discounted cash pricing, nationwide pharmacy access, and a trusted consumer platform that helps patients start treatment while maintaining continuity of care and the ability to fill prescriptions at their pharmacy of choice.
About GoodRx
GoodRx is the leading platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.
?GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
GoodRx Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of Foundayo (orforglipron), Zepbound (tirzepatide) KwikPen and related pricing; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260409583467/en/
Media Contact
press@goodrx.com
Original: GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide
US Market News
4月前
GoodRx Powers Pricing for Leading Brand Medications on TrumpRxFebruary 5, 2026 7:44 PM
Business Wire
Brief Summary:
GoodRx is a core integration partner for TrumpRx, powering the pricing for leading brand medications
At launch, GoodRx is the integrated pricing source on TrumpRx for Pfizer, including over 30 of Pfizer’s essential brand medications spanning women’s health, arthritis, and more
By unifying pricing, pharmacy enablement, and a trusted consumer experience, GoodRx enables pharma manufacturers to rapidly deploy and scale emerging pricing models with minimal operational lift
GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on TrumpRx.
TrumpRx is a website that lists discounted cash prices from pharmaceutical manufacturers. TrumpRx does not sell or dispense drugs. Instead, TrumpRx facilitates consumer access to the selected discount, and then the underlying partner platform executes the pricing.
At launch, GoodRx is the integrated pricing source for Pfizer, including over 30 of Pfizer’s essential brand medications, along with other leading pharmaceutical manufacturers. Additional manufacturer integrations are expected to follow.
“Transparent direct-to-consumer prescription pricing helps to ensure millions of Americans have access to the healthcare they deserve,” said Wendy Barnes, President and CEO of GoodRx. “GoodRx gives manufacturers a proven way to launch discounted cash pricing at scale and extend it directly into TrumpRx. We’re starting with essential brand medications from Pfizer and other manufacturers, with additional programs coming soon. Together, we’re turning the promise of prescription drug affordability into a reality for millions of Americans.”
Significant Savings for Over 30 Pfizer Medications Available via GoodRx
Coinciding with the TrumpRx launch, Pfizer is introducing significant discounts for more than 30 of its essential brand medications spanning women’s health, migraine, arthritis, rare disease, and more. Eligible patients may find the prices on TrumpRx and then seamlessly access the GoodRx-enabled savings that range as high as 85% and on average 50%, for the large majority of Pfizer’s primary care treatments and select specialty brands.
To help consumers find these new low prices through a simple and trusted entry point, GoodRx has launched its Pfizer-branded digital storefront.
How GoodRx Helps Pharma Operationalize the TrumpRx Approach
This announcement reinforces GoodRx’s role as a proven integration layer for emerging pricing models. By offering manufacturers a turnkey, scalable way to publish discounted cash prices and extend them to TrumpRx, GoodRx reduces complexity by unifying pricing, pharmacy enablement, and a trusted consumer experience into a single solution. As a result, manufacturers can rapidly operationalize most favored nation (MFN) and other policy-aligned pricing programs at national scale, helping reach more patients, accelerating adoption, and supporting consistently accessible savings at the pharmacy counter.
About GoodRx
GoodRx is the leading platform for prescription savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.
?GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of GoodRx’s partnership with Pfizer or TrumpRx; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260205677365/en/
Media Contact
press@goodrx.com
Original: GoodRx Powers Pricing for Leading Brand Medications on TrumpRx
iHub News
4月前
60 Degrees Pharmaceuticals shares slide after unveiling GoodRx collaborationFebruary 2, 2026 11:07 AM
IH Market News
Shares of 60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP) fell about 16.9% in premarket trading on Monday after the company announced a new partnership with GoodRx (NASDAQ:GDRX) aimed at expanding access to its malaria prevention treatment, ARAKODA.The deal will allow eligible consumers to receive discounts of up to 30% on ARAKODA (tafenoquine), which is currently the only FDA-approved, once-weekly prescription medication for malaria prevention available in the United States. Through GoodRx’s network, patients will be able to obtain the drug at more than 70,000 pharmacies nationwide starting February 2, 2026, or opt for home delivery where available.ARAKODA is primarily prescribed to travelers visiting malaria-endemic regions. The therapy was developed by the Walter Reed Army Institute of Research and received FDA approval in 2018. Its long terminal half-life of roughly 16 days enables less frequent dosing compared with other prophylactic malaria treatments.The standard dosing schedule involves an initial loading phase of two 100 mg tablets taken daily for three days prior to travel, followed by a maintenance dose of two 100 mg tablets once weekly during travel for up to six months, and a final two-tablet dose in the week after returning.Despite the potential for broader patient access through the GoodRx platform, the market reacted negatively to the announcement, with investors pushing the stock sharply lower in early trading.60 Degree Pharmaceuticals stock priceGoodRx stock price
Original: 60 Degrees Pharmaceuticals shares slide after unveiling GoodRx collaboration
US Market News
4月前
GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference CallJanuary 28, 2026 4:05 PM
Business Wire
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, February 26, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook.
To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company’s investor relations website at https://investors.goodrx.com, where accompanying materials will be posted prior to the conference call.
Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.goodrx.com for at least 30 days.
About GoodRx
GoodRx is the leading platform for prescription savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.
GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128619763/en/
Investor Contact
GoodRx
ir@goodrx.com
Media Contact
GoodRx
press@goodrx.com
Original: GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
@LaughinPaulRyan
6年前
... TRUMP $GDRX BOOM ... #LOOTWALLSTREET
TODAY @REALDONALDTRUMP WILL RUIN AMAZON PHARMACY DREAMS.
At most stops, however, Trump has at least attempted to broach one topic that pollsters have repeatedly found to be resonant with voters: the high cost of prescription drugs. And time and again, Trump has not only promised to cut them – “Drug prices will be coming down 80 or 90 percent,” he said during the first presidential debate – but insisted that, functionally, he has already done so.
Do pharmacies have to accept GoodRx?
More than 70,000 pharmacies in the United States — including major chains like Costco, Kroger, Walmart, CVS, Rite Aid and Walgreens — will accept GoodRx. ... Participating pharmacies are contractually obligated to accept GoodRx coupons. If your pharmacist refuses to accept them, you can call GoodRx at (855) 268-2822. - source
It’s a strong claim in an election year. Is there hard evidence to support it?
“Evidence exists – but it’s to the contrary,” said Anthony Wright, executive director of Health Access California, a consumer advocacy group. “Drug prices continue to go up and up, and what’s remarkable is how true that is across the board. Newer drugs, older ones, brand names, generics – the prices for all of them are climbing.”
Drug prices in the U.S. rose by 3% from 2018 to 2019, part of a 4.6% overall increase in the cost of medical care.
So say the numbers, Trump’s bluster to the contrary. According to the Bureau of Labor Statistics, drug prices in the U.S. rose by 3% from 2018 to 2019, part of a 4.6% overall increase in the cost of medical care in this country. By July of this year, the prescription cost site GoodRx had recorded an average price hike of nearly 7% among more than 850 brand and generic drugs for 2020.
The issue has an urgency that goes beyond the ballot. In a year of the coronavirus pandemic, with millions of Americans out of work and either absent health insurance or about to be cut from employers’ plans, every hint of a rise in costs feels epic – and continuing increases could be devastating for low and middle income families alike. But even coming into the election cycle, before COVID-19 dominated the conversation, prescription drug prices were near the top of voters’ concerns about health care. - source
@LaughinPaulRyan
6年前
GoodRx Holdings Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform in the United States, today announced that executives from the Company will be presenting at the following virtual investor conferences:
RBC Capital Markets Global Technology, Internet, Media and Telecom Virtual Conference on Wednesday, November 18, at 7:15am PT
Credit Suisse 24th Annual Technology Conference on Thursday, December 3, at 9:50am PT
UBS Global TMT Virtual Conference on Tuesday, December 8, at 11:50am PT
Barclays Global Technology, Media and Telecommunications Conference on Thursday, December 10, at 10:00am PT
Live webcasts of each presentation and any accompanying presentation materials, as well as the archived recordings, will be available on the Investor Relations section of the Company’s website, https://investors.goodrx.com/. Following each conference, archived recordings will be available on the Company’s website for at least 30 days.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
glenn1919
4月前
hyborianwar
8月前
tw0122
10月前
Monksdream
3年前
conix
4年前
T695
6年前
crudeoil24
6年前
メールアドレスで登録
